Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its proprietary ProCellEx庐 plant cell-based expression system, will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference. The event will take place on Tuesday, May 20, 2025, at the Nasdaq headquarters in New York City.
The company's Sr. Vice President and CFO, Eyal Rubin, will deliver a presentation and be available for one-on-one meetings with investors. The presentation will be webcast live at 4:30 pm EDT and can be accessed through the company's investor relations website or via the provided webcast link.
Protalix BioTherapeutics (NYSE American: PLX), un'azienda biofarmaceutica specializzata in proteine terapeutiche ricombinanti tramite il suo esclusivo sistema di espressione basato su cellule vegetali ProCellEx庐, parteciper脿 al 3掳 Annuale H.C. Wainwright BioConnect Investor Conference. L'evento si terr脿 marted矛 20 maggio 2025 presso la sede del Nasdaq a New York City.
Il Senior Vice President e CFO dell'azienda, Eyal Rubin, presenter脿 un intervento e sar脿 disponibile per incontri individuali con gli investitori. La presentazione sar脿 trasmessa in diretta webcast alle 16:30 EDT e sar脿 accessibile tramite il sito web delle relazioni con gli investitori dell'azienda o tramite il link webcast fornito.
Protalix BioTherapeutics (NYSE American: PLX), una compa帽铆a biofarmac茅utica especializada en prote铆nas terap茅uticas recombinantes utilizando su sistema exclusivo de expresi贸n basado en c茅lulas vegetales ProCellEx庐, participar谩 en la 3陋 Conferencia Anual de Inversores H.C. Wainwright BioConnect. El evento se llevar谩 a cabo el martes 20 de mayo de 2025 en la sede de Nasdaq en la ciudad de Nueva York.
El Vicepresidente Senior y CFO de la compa帽铆a, Eyal Rubin, realizar谩 una presentaci贸n y estar谩 disponible para reuniones individuales con inversores. La presentaci贸n se transmitir谩 en vivo por webcast a las 4:30 pm EDT y podr谩 accederse a trav茅s del sitio web de relaciones con inversores de la compa帽铆a o mediante el enlace de webcast proporcionado.
Protalix BioTherapeutics (NYSE American: PLX)電� 霃呾瀽鞝侅澑 ProCellEx庐 鞁濍 靹疙彫 旮半皹 氚滍槃 鞁滌姢韰滌潉 靷毄頃橃棳 鞛“頃� 旃橂 雼氨歆堨潉 鞝勲鞙茧 頃橂姅 靸濍獏瓿淀暀 須岇偓搿�, 鞝�3須� 鞐半 H.C. Wainwright BioConnect 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃╇媹雼�. 頄夓偓電� 2025雲� 5鞗� 20鞚� 頇旍殧鞚� 雺挫殨鞁� 雮橃姢雼� 氤胳偓鞐愳劀 臧滌禍霅╇媹雼�.
須岇偓鞚� 靾橃劃 攵�靷灔鞚挫瀽 CFO鞚� 鞐愳杽 耄箞(Eyal Rubin)鞚� 氚滍憸毳� 歆勴枆頃橂┌ 韴瀽鞛愲摛瓿� 鞚茧寑鞚� 氙疙寘霃� 歆勴枆頃� 鞓堨爼鞛呺媹雼�. 氚滍憸電� 霃欕秬 響滌鞁� 旮办 鞓ろ泟 4鞁� 30攵勳棎 靸濎瓿勲悩氅�, 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼雮� 鞝滉车霅� 鞗轨簮鞀ろ姼 毵來伂毳� 韱淀暣 鞝戩啀頃� 靾� 鞛堨姷雼堧嫟.
Protalix BioTherapeutics (NYSE American : PLX), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les prot茅ines th茅rapeutiques recombinantes utilisant son syst猫me d'expression propri茅taire bas茅 sur des cellules v茅g茅tales ProCellEx庐, participera 脿 la 3e conf茅rence annuelle des investisseurs H.C. Wainwright BioConnect. L'茅v茅nement aura lieu le mardi 20 mai 2025 au si猫ge du Nasdaq 脿 New York.
Le vice-pr茅sident principal et directeur financier de la soci茅t茅, Eyal Rubin, fera une pr茅sentation et sera disponible pour des r茅unions individuelles avec les investisseurs. La pr茅sentation sera diffus茅e en direct par webcast 脿 16h30 EDT et pourra 锚tre consult茅e via le site web des relations investisseurs de la soci茅t茅 ou par le lien webcast fourni.
Protalix BioTherapeutics (NYSE American: PLX), ein biopharmazeutisches Unternehmen, das sich auf rekombinante therapeutische Proteine mit seinem propriet盲ren ProCellEx庐-Pflanzenzell-Expressionssystem spezialisiert hat, wird an der 3. j盲hrlichen H.C. Wainwright BioConnect Investor Conference teilnehmen. Die Veranstaltung findet am Dienstag, den 20. Mai 2025, im Nasdaq-Hauptquartier in New York City statt.
Der Senior Vice President und CFO des Unternehmens, Eyal Rubin, wird eine Pr盲sentation halten und f眉r Einzelgespr盲che mit Investoren zur Verf眉gung stehen. Die Pr盲sentation wird um 16:30 Uhr EDT live per Webcast 眉bertragen und kann 眉ber die Investor-Relations-Website des Unternehmens oder den bereitgestellten Webcast-Link abgerufen werden.
- None.
- None.
CARMIEL,
Eyal Rubin, the Company's Sr.听Vice President and Chief Financial Officer, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.
Investors interested in scheduling a meeting with the Company's management team should contact their H.C. Wainwright representative or email [email protected].
Event Details
颁辞苍蹿别谤别苍肠别:听听 3rd Annual H.C. Wainwright BioConnect Investor Conference
Date:听听听听听听听听听听听听听听 Tuesday, May听20, 2025
尝辞肠补迟颈辞苍:听听听听听听听 Nasdaq World Headquarters in
Webcast Details
A听webcast of the live presentation will be available at 4:30 pm, Eastern Daylight Time听(EDT), via the following links:
Company Link:听听听听听听听听
Webcast Link:听听听听听听听听听听 https://journey.ct.events/view/c15f7813-e688-4a3e-911e-358a9c0562b8
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX鈥�115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX鈥�119, a plant cell-expressed long acting DNase听I for the treatment of NETs-related diseases; and others.
Investor Contact:听
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
[email protected]听
Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
听
View original content:
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When is Protalix BioTherapeutics (PLX) presenting at the H.C. Wainwright Conference?
Who will represent Protalix BioTherapeutics (PLX) at the H.C. Wainwright Conference?
How can investors access Protalix BioTherapeutics' (PLX) presentation at the conference?
How can investors schedule meetings with Protalix BioTherapeutics' (PLX) management?
